ClinicalTrials.gg
Not yet recruitingNCT07375836Updated Feb 4, 2026

The Effect of Chocolate Consumption During Labor on Second Stage Duration

An interventional study of 50 g of milk chocolate cocoa content 25-30% in Labor, Second Stage of Labor and Pregnancy, sponsored by Hillel Yaffe Medical Center. Not yet recruiting. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Hillel Yaffe Medical Center · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Childbirth is an energy-intensive physiological process, requiring sustained effort comparable in intensity to moderate physical activity. Studies suggest that providing an available energy source during labor, such as dextrose infusion or natural carbohydrate-rich foods such as dates, may shorten the duration of labor and improve cervical dilation without adversely affecting obstetric outcomes. The primary objective of the study is to examine whether giving chocolate during labor affects the duration of the second stage of labor, compared to a control group that will not receive a nutritional intervention. The study is a prospective, randomized, controlled trial that will be conducted in the delivery room of Hillel Yaffe Medical Center. Healthy pregnant women with a singleton pregnancy at ≥37 weeks gestational age, in spontaneous or induced labor, without diabetes (pre/gestational), will be recruited to participate. Participants in the intervention group will receive one serving of 50 grams of milk chocolate (cocoa content 25-30%, without filling or additives) at a cervical dilation of 6 cm or more (and not yet fully dilated). The mother will be asked to consume the serving gradually over 30 minutes. Milk chocolate was chosen because it is better tolerated compared to dark chocolate, has a more gentle profile of active ingredients (which can increase nausea and heartburn) and provides a source of available carbohydrates. The study will be conducted in accordance with the guidelines of the Ministry of Health's procedure for medical experiments on humans, and will be conducted after approval by the Institutional Helsinki Committee.

02

Conditions studied

  • Labor
  • Second Stage of Labor
  • Pregnancy

Keywords

  • Second stage of labor
  • Oral carbohydrate intake
  • Non-pharmacologic intervention
  • Maternal exhaustion
  • Pregnancy
  • Labor
  • Randomized controlled trial
03

In context

Lead sponsor

Hillel Yaffe Medical Center is the lead sponsor of 305 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gestational age ≥37 weeks
  2. Single fetus in cephalic presentation
  3. Spontaneous or induced labor in the active phase (dilation ≥ 5 cm).
  4. Normal assessment of the mother and fetus upon admission to the delivery room (normal indices, normal monitoring and biophysical profile)
  5. 18-35 -

Exclusion criteria

Exclusion Criteria:

  1. Multiple pregnancies
  2. Gestational age \<37 weeks
  3. Gestational or pre-gestational diabetes
  4. Significant underlying diseases
  5. Previous cesarean section/myomectomy
  6. Known significant fetal malformation
  7. Sensitivity to chocolate ingredients
  8. Lack of documentation of necessary information -
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    50 g of milk chocolate cocoa content 25-30%

    . Participants in the intervention group will receive one serving of 50 grams of milk chocolate (cocoa content 25-30%, without filling or additives) at a cervical dilation of 6 cm or more. The mother will be asked to consume the serving gradually over 30 minutes.

    Other: 50 g of milk chocolate cocoa content 25-30%

  • No intervention
    control group - no intervention

    Participants in the control group will receive routine care as is customary in the delivery room, without any proactive nutritional supplementation.

Interventions

  • Other50 g of milk chocolate cocoa content 25-30%

    Milk chocolate was chosen as it is better tolerated compared to dark chocolate, has a milder profile of active ingredients (which can increase nausea and heartburn) and provides a source of available carbohydrates. A dose of 50 grams was chosen that provides 25-30 grams of simple carbohydrates - sufficient for a significant increase in blood glucose but low enough to prevent a sudden sugar load or nausea. The intervention will be given at 6-9 cm dilation, towards the transition to the second phase - to allow the absorption of glucose and neurochemicals to be deafened at a time when the body needs increased energy and alertness. Giving it earlier may result in the effect of the chocolate wearing off before the second phase, and later - there will be no time for effective absorption.

06

What researchers measure

Primary outcomes

  1. Duration of second stage of labor

    The duration of the second stage of labor, defined as the time in minutes from full cervical dulation (10cm) to delivery of the neonate.

    Time frame: From full cervical dilation to delivery

Secondary outcomes

  1. Mode of delivery

    Mode of delivery categorized as spontanous vaginal delivery, operative vaginal delivery (vacuum), or cesarean delivery

    Time frame: At delivery

  2. Maternal nausea or vomiting during labor

    The occurrence of maternal nausea or vomiting during labor following the assigned intervention, as documented in the medical record

    Time frame: From intervention administration untill discharge from labor room

  3. Neonatal Apgar score at 1 and 5 minutes

    The Apgar score is assessed at 1 and 5 minutes after delivery. The total score ranges from 0 to 10, with higher scores indicating better neonatal condition.

    Time frame: 1 and 5 minutes after delivery

  4. Umbilical cord blood glucose level

    Umbilical cord blood glucose concentration measured from umbelical blood collected immediately after delivery (when a cord blood sample is obtained per routine practice

    Time frame: at delivery

  5. Maternal heart rate

    Maternal heart rate measured in beats per minute as recorded by continous intrapartum maternal monitorind

    Time frame: During the second stage of labor

  6. Umbelical cord blood PH

    Umbelical cord blood PH measures immediatley after delivery

    Time frame: At delivery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Jan 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 29, 2026
StartEst.
Feb 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07375836
Responsible party
Sponsor
First posted
Jan 29, 2026
Start date
Feb 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 4, 2026

Study contacts

Libby O Madar, M.D
Contact
NoaAl@hymc.gov.il
+972-4-7744602
Rinat Gabbay-Benziv, M.D
Contact
+972-4-7744514

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion